Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPI-818 in moderate to severe atopic dermatitis
ChiCTR2500110450Phase 2Recruiting
- Sponsor
- Shanghai Skin Disease Hospital
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of soquelitinib in atopic dermatitis (AD) (11 cohorts), sponsored by Shanghai Skin Disease Hospital. Primary endpoint: Treatment-emergent adverse events. Started Oct 2025; status: recruiting.
02
Drugs
soquelitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2500110450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110450.